Nordic Cancer Therapeutics Market Outlook (2021-2031)
The Nordic Cancer Therapeutics Market size was valued at US$ 3,960.76 Mn in 2024 and is projected to reach US$ 8,134.39 Mn by 2031, growing at a CAGR of 10.93% during 2025 - 2031.
Report Coverage
- Therapy Type: Chemotherapy, Targeted Therapy, Radiation Therapy, Hormone Therapy, Other Therapy Types
- Indications: Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver & Intrahepatic Bile Duct Cancer, Thyroid Cancer, Other Indications
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Channel
US$ 3,960.76 Mn
Market size in 2024
US$ 8,134.39 Mn
Market Size by 2031
10.93%
CAGR, 2025 - 2031
2025-2031
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Nordic Cancer Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Nordic Cancer Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Nordic Cancer Therapeutics Market Regional Analysis
6.2 Nordic Cancer Therapeutics Market Revenue 2021-2031 (US$ Million)
6.3 Nordic Cancer Therapeutics Market Forecast Analysis
7. Nordic Cancer Therapeutics Market Analysis – by Therapy Type
7.1 Chemotherapy
- 7.1.1 Overview
- 7.1.2 Chemotherapy: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Targeted Therapy
- 7.2.1 Overview
- 7.2.2 Targeted Therapy: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Radiation Therapy
- 7.3.1 Overview
- 7.3.2 Radiation Therapy: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Hormone Therapy
- 7.4.1 Overview
- 7.4.2 Hormone Therapy: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Other Therapy Types
- 7.5.1 Overview
- 7.5.2 Other Therapy Types: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Nordic Cancer Therapeutics Market Analysis – by Indications
8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Lung Cancer: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Colorectal Cancer
- 8.4.1 Overview
- 8.4.2 Colorectal Cancer: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Prostate Cancer
- 8.5.1 Overview
- 8.5.2 Prostate Cancer: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Stomach Cancer
- 8.6.1 Overview
- 8.6.2 Stomach Cancer: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Cervical Cancer
- 8.7.1 Overview
- 8.7.2 Cervical Cancer: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.8 Liver & Intrahepatic Bile Duct Cancer
- 8.8.1 Overview
- 8.8.2 Liver & Intrahepatic Bile Duct Cancer: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.9 Thyroid Cancer
- 8.9.1 Overview
- 8.9.2 Thyroid Cancer: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.10 Other Indications
- 8.10.1 Overview
- 8.10.2 Other Indications: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Nordic Cancer Therapeutics Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Channel
- 9.3.1 Overview
- 9.3.2 Online Channel: Nordic Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Nordic Cancer Therapeutics Market – Nordic Analysis
10.1 Overview
10.2 Nordic- 10.2.1 Nordic Cancer Therapeutics Market Breakdown, by Key Country, 2025 and 2031 (%)
- 10.2.1.1 Nordic Cancer Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.2.1.1 Sweden: Nordic Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.1.1 Sweden: Nordic Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.1.2 Sweden: Nordic Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.1.3 Sweden: Nordic Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.2 Denmark: Nordic Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.2.1 Denmark: Nordic Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.2.2 Denmark: Nordic Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.2.3 Denmark: Nordic Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.3 Norway: Nordic Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.3.1 Norway: Nordic Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.3.2 Norway: Nordic Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.3.3 Norway: Nordic Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.4 Finland: Nordic Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.4.1 Finland: Nordic Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.4.2 Finland: Nordic Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.4.3 Finland: Nordic Cancer Therapeutics Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Astellas Pharma Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Eli Lilly and Co
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Novartis AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Merck KGaA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 AstraZeneca
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Pfizer Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Hoffmann-La Roche Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Johnson & Johnson
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 AbbVie Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Bristol-Myers Squibb Co
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Access the Full N Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
